Download PDF

1. Company Snapshot

1.a. Company Description

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices.


It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments.The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings.It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services.


The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets.The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Show Full description

1.b. Last Insights on TFX

Teleflex Incorporated's recent performance was negatively impacted by its Q4 earnings and revenue miss, with earnings per share of $1.93, falling short of the Zacks Consensus Estimate of $3.73. Margins also contracted, contributing to the underperformance. Additionally, Citigroup Inc. reduced its stake in the company by 40.0%, selling 14,020 shares. The company's portfolio reshuffle and 2026 growth guidance somewhat offset the miss, but the overall earnings miss and shrinking margins remain a concern. Pomerantz LLP's ongoing investigation into claims on behalf of investors adds to the negative sentiment.

1.c. Company Highlights

2. Teleflex Incorporated's Strategic Divestiture and Future Growth Prospects

In 2025, Teleflex Incorporated reported adjusted earnings per share of $6.98, an 8.7% increase year over year. The company's financial performance was marked by a significant transaction - the signing of definitive agreements to sell its acute care interventional urology and OEM businesses for $2.03 billion, resulting in net after-tax proceeds of approximately $1.8 billion. For 2026, the company expects pro forma adjusted constant currency revenue growth of 4.5% to 5.5% and adjusted EPS in the range of $6.25 to $6.55. The guidance includes $90 million in stranded costs associated with the separation activities.

Publication Date: Mar -02

📋 Highlights
  • Divestiture Proceeds:: Sold acute care interventional urology and OEM businesses for $2.03B, netting $1.8B after-tax, to fund $1B share buybacks and $800M debt paydown.
  • 2025 EPS Growth:: Adjusted EPS rose 8.7% to $6.98 YoY, driven by focused Vascular, Interventional, and Surgical portfolio post-Teleflex RemainCo reorganization.
  • 2026 Guidance:: Pro forma revenue growth of 4.5–5.5% and adjusted EPS of $6.25–$6.55, including $90M stranded costs offset by TSA/MSA agreements and $50M annual restructuring savings.
  • Stranded Cost Mitigation:: $90M in separation costs fully offset by transition/service agreements and $50M+ annual savings from restructuring, including $50M post-2026 from Biotronik integration.
  • Future EPS Momentum:: 2026–2027 EPS growth projected due to debt reduction, share repurchases, and operating leverage, with surgical segment showing double-digit growth from instrument and ligation demand.

Operational Highlights and Restructuring

The creation of Teleflex RemainCo resulted in a more focused portfolio centered on Vascular, Interventional, and Surgical businesses. The company's Surgical segment saw double-digit growth in most franchises, driven by strength in the instrument portfolio and ligation. Teleflex has approved a restructuring plan to eliminate a portion of the stranded costs, targeting approximately $50 million in annual pretax savings. The restructuring program is expected to yield $48 million to $52 million in savings, some of which is already included in the $6.25 to $6.55 EPS guidance range.

Capital Allocation and Debt Reduction

Teleflex plans to utilize the net proceeds from the divestiture to return significant capital to shareholders through a $1.0 billion share repurchase authorization and reduce debt. The company expects to pay down $800 million of debt, with $700 million going towards the deferred draw revolver for the Biotronik acquisition and $100 million towards its revolver. The debt reduction and share buybacks are expected to drive meaningful increases in adjusted earnings per share in 2026 and 2027.

Valuation and Growth Prospects

With a P/E Ratio of -5.96 and an EV/EBITDA of 17.19, the market's expectations for Teleflex's future growth are mixed. The company's ROE is -23.7%, indicating potential challenges in generating returns on equity. However, the expected pro forma revenue growth of 4.5% to 5.5% in 2026 and mid-single-digit growth in 2027, driven by the focused portfolio and successful integration of Biotronik, may lead to significant EPS uplift due to share buybacks and debt paydown.

Integration and Synergies

The company is focused on integrating Biotronik, with successful Salesforce integration, retention of employees, and revenue synergies expected. R&D investment is expected to be around 8% of revenue for RemainCo, driven by Biotronik and additional investments in Interventional and Vascular. The successful integration and realization of synergies are crucial to achieving the expected growth prospects and improving the company's financial performance.

3. NewsRoom

Card image cap

Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

11:30

Source: businesswire.com

Card image cap

Teleflex Incorporated (NYSE:TFX) Given Average Recommendation of “Hold” by Brokerages

Mar -20

Source: defenseworld.net

Card image cap

Cinctive Capital Management LP Invests $3.97 Million in Teleflex Incorporated $TFX

Mar -16

Source: defenseworld.net

Card image cap

917,925 Shares in Teleflex Incorporated $TFX Purchased by Abrams Bison Investments LLC

Mar -15

Source: defenseworld.net

Card image cap

366,553 Shares in Teleflex Incorporated $TFX Purchased by Capital International Investors

Mar -13

Source: defenseworld.net

Card image cap

Teleflex Incorporated $TFX Holdings Decreased by Citigroup Inc.

Mar -07

Source: defenseworld.net

Card image cap

Focus Partners Advisor Solutions LLC Takes $1.36 Million Position in Teleflex Incorporated $TFX

Mar -06

Source: defenseworld.net

Card image cap

Teleflex: More Clarity And More Questions

Mar -03

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.61%)

6. Segments

Americas

Expected Growth: 4.5%

Teleflex Incorporated's 4.5% growth in Americas is driven by increasing demand for its medical technologies, particularly in the vascular access and anesthesia segments. Strong sales of its Arrow PICC and EZ-IO products, as well as growth in its OEM business, contribute to this growth. Additionally, the company's strategic acquisitions and investments in emerging markets also support its expansion in the region.

EMEA

Expected Growth: 4.8%

EMEA growth of 4.8% at Teleflex Incorporated is driven by increasing demand for vascular access and anesthesia products, expansion in emerging markets, and strategic acquisitions. Additionally, a growing focus on patient safety and infection prevention, as well as an aging population, contribute to the region's growth.

Asia

Expected Growth: 5.2%

Teleflex Incorporated's 5.2% growth in Asia is driven by increasing demand for medical devices, particularly in China and India, fueled by a growing middle class, government investments in healthcare infrastructure, and an aging population. Additionally, the company's strategic expansion into emerging markets and partnerships with local distributors have contributed to its growth in the region.

Original Equipment Manufacturer and Development Services

Expected Growth: 4.2%

Teleflex Incorporated's Original Equipment Manufacturer and Development Services segment growth of 4.2% is driven by increasing demand for medical devices, strategic partnerships, and expansion into emerging markets. Additionally, investments in research and development, and a focus on innovative product offerings have contributed to this growth.

7. Detailed Products

Vascular Access

Teleflex offers a range of vascular access products, including arterial and central venous catheters, guidewires, and introducers, designed to facilitate minimally invasive procedures and improve patient outcomes.

Anesthesia

Teleflex provides a comprehensive range of anesthesia products, including laryngoscopes, anesthesia masks, and breathing circuits, designed to support safe and effective anesthesia delivery.

Respiratory

Teleflex offers a range of respiratory products, including oxygen therapy devices, ventilators, and respiratory care accessories, designed to support patient respiratory care.

Surgical

Teleflex provides a range of surgical products, including surgical instruments, sutures, and staplers, designed to support minimally invasive and open surgical procedures.

Interventional

Teleflex offers a range of interventional products, including guidewires, catheters, and angioplasty balloons, designed to support minimally invasive interventional procedures.

Urology

Teleflex provides a range of urology products, including urological instruments, catheters, and stents, designed to support urological procedures and patient care.

8. Teleflex Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

Teleflex Incorporated operates in the medical technology industry, where substitutes are limited. However, the company faces competition from alternative medical devices and procedures, which can substitute its products.

Bargaining Power Of Customers

Teleflex Incorporated sells its products to hospitals, clinics, and medical professionals, who have limited bargaining power due to the specialized nature of the products.

Bargaining Power Of Suppliers

Teleflex Incorporated relies on a diverse supplier base, which reduces the bargaining power of individual suppliers. However, the company may face supply chain disruptions and price increases from key suppliers.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including regulatory hurdles, significant research and development investments, and established distribution networks, making it difficult for new entrants to compete with Teleflex Incorporated.

Intensity Of Rivalry

The medical technology industry is highly competitive, with established players competing for market share. Teleflex Incorporated faces intense competition from companies such as Medtronic, Stryker, and Johnson & Johnson.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 30.25%
Debt Cost 5.36%
Equity Weight 69.75%
Equity Cost 9.53%
WACC 8.27%
Leverage 43.38%

11. Quality Control: Teleflex Incorporated passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Hologic

A-Score: 4.7/10

Value: 3.0

Growth: 4.2

Quality: 7.1

Yield: 0.0

Momentum: 5.0

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Merit Medical Systems

A-Score: 4.2/10

Value: 2.7

Growth: 7.3

Quality: 5.3

Yield: 0.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Teleflex

A-Score: 3.7/10

Value: 6.2

Growth: 3.4

Quality: 5.1

Yield: 1.0

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Haemonetics

A-Score: 3.7/10

Value: 4.0

Growth: 6.2

Quality: 6.3

Yield: 0.0

Momentum: 2.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Repligen

A-Score: 3.6/10

Value: 0.4

Growth: 5.0

Quality: 5.1

Yield: 0.0

Momentum: 7.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Cooper

A-Score: 3.2/10

Value: 2.6

Growth: 2.0

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 6.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

115.96$

Current Price

115.97$

Potential

-0.00%

Expected Cash-Flows